Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corvus Pharma Com 901 Gateway Boulevard Third Floor South San Francisco CA 94080 USA

www.corvuspharma.com Employees: 37 P: 650-900-4520

Sector:

Medical

Description:

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Key Statistics

Overview:

Market Capitalization, $K 1,119,613
Enterprise Value, $K 1,115,033
Shares Outstanding, K 83,992
Float, K 60,054
% Float 71.50%
Short Interest, K 16,010
Short Float 19.06%
Days to Cover 13.29
Short Volume Ratio 0.66
% of Insider Shareholders 28.50%
% of Institutional Shareholders 46.64%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -15,280 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -12,320 K
EBIT, $ -42,970 K
EBITDA, $ -44,210 K

Growth:

1-Year Return 219.03%
3-Year Return 1,860.58%
5-Year Return 334.20%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 87.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 03/12/26
Next Earnings Date 05/14/26
Earnings Per Share ttm -0.50
EPS Growth vs. Prev Qtr -25.00%
EPS Growth vs. Prev Year 16.67%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

CRVS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -23.58%
Return-on-Assets % -20.60%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow 111.16
Price/Book 19.28
Book Value/Share 0.73
Interest Coverage -0.65
60-Month Beta 0.78
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.